Adocia

Regulatory Filings • Jun 2, 2016

PRESS RELEASE

Adocia to Present at the Jefferies 2016 Global Healthcare Conference

Lyon, France, June 02, 2016 – Adocia, a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, announced today that Dr. Gérard Soula, the Company's President and Chief Executive Officer, has been invited to present at the Jefferies 2016 Global Healthcare Conference being held on June 7-10, 2016 at the Grand Hyatt Hotel in New York City.

Dr. Soula is scheduled to present on Thursday, June 9, 2016 at 10:30 AM EDT. The presentation will take place in Ballroom 1.

The conference will feature a widespread range of public & private companies across the healthcare sector and executives from the investment community. The event will include company presentations, Q&A breakout sessions and thematic panels.

A live-streaming webcast will be available at http://wsw.com/webcast/jeff97/adoc. The archived presentation will be available for 90 days following the event.

About ADOCIA

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia's insulin formulation portfolio, featuring four clinical-stage products and one preclinical products, is among the largest and most differentiated in the industry.

The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application in order to address specific patient needs.

Adocia's clinical pipeline includes a unique formulation of PDGF-BB for the treatment of diabetic foot ulcer and four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a rapid-acting formulation of human insulin (HinsBet U100) and a combination of insulin glargine and a rapid-acting insulin analog (BioChaperone Combo). Adocia is also developing a concentrated, rapid-acting formulation of human insulin (HinsBet U500). In December 2014, Adocia signed a partnership with Eli Lilly for the development and commercialization of the BioChaperone Lispro projects.

Adocia's extended, early-stage programs include innovative monoclonal antibody formulations, featuring two ongoing collaborations programs with major pharmaceutical companies in the field, and the delivery of anticancer drugs using the proprietary DriveIn® nanotechnology platform.

Adocia aims to deliver "Innovative medicine for everyone, everywhere."

To learn more about Adocia, please visit us at www.adocia.com

For more information please contact:

Adocia	Adocia Press Relations Europe	Adocia Investor Relations USA
Gérard Soula	MC Services AG	The Ruth Group
Chairman and CEO contactinvestisseurs@adocia.com Tél. : +33 4 72 610 610	Raimund Gabriel raimund.gabriel@mc-services.eu adocia@mc-services.eu Tél. : +49 89 210 228 0	Tram Bui tbui@theruthgroup.com Tel.: +646.536.7035

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia shares in any jurisdiction.